UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1478-1
Program Prior Authorization/Notification
Medications Nemluvio® (nemolizumab-ilto)
P&T Approval Date 6/2025
Effective Date 9/1/2025
1. Background:
Nemluvio (nemolizumab-ilto) is an interleukin-31 receptor antagonist indicated for the
treatment of adults with prurigo nodularis and for the treatment of adults and pediatric patients
12 years of age and older with moderate to severe atopic dermatitis in combination with topical
corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with
topical prescription therapies.
2. Coverage Criteriaa:
A. Atopic Dermatitis
1. Initial Authorization
a. Nemluvio will be approved based on all of the following criteria:
(1) Diagnosis of moderate to severe atopic dermatitis
-AND-
(2) Will be used in combination with topical corticosteroids and/or calcineurin
inhibitors when the disease is not adequately controlled with topical prescription
therapies
-AND-
(3) Patient is not receiving Nemluvio in combination with either of the following for
treatment of the same indication:
(a) Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm), Dupixent
(dupilumab), Ebglyss (lebrikizumab-lbkz)]
(b) Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib),
Opzelura (topical ruxolitinib), Cibinqo (abrocitinib)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Nemluvio will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Nemluvio therapy
© 2025 UnitedHealthcare Services, Inc.
1
-AND-
(2) Patient is not receiving Nemluvio in combination with either of the following for
treatment of the same indication:
(a) Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm), Dupixent
(dupilumab), Ebglyss (lebrikizumab-lbkz)]
(b) Janus kinase inhibitor [e.g., Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib),
Opzelura (topical ruxolitinib), Cibinqo (abrocitinib)]
Authorization will be issued for 12 months.
B. Prurigo Nodularis
1. Initial Authorization
a. Nemluvio will be approved based on both of the following criteria:
(1) Diagnosis of prurigo nodularis
-AND-
(2) Patient is not receiving Nemluvio in combination with Dupixent for treatment of the
same indication
Authorization will be issued for 12 months.
2. Reauthorization
a. Nemluvio will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Nemluvio therapy
-AND-
(2) Patient is not receiving Nemluvio in combination with Dupixent for treatment of the
same indication
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
© 2025 UnitedHealthcare Services, Inc.
2
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limitations may be in place.
• Medical Necessity may be in place.
4. References:
1. Nemluvio [package insert]. Dallas, TX: Galderma Laboratories, L.P., December 2024.
Program Prior Authorization/Notification - Nemluvio (nemolizumab-ilto)
Change Control
6/2025 New program.
© 2025 UnitedHealthcare Services, Inc.
3